Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DENV MTase Inhibitor
CNP0296775 is a potent inhibitor of dengue virus methyltransferase (DENV MTase), targeting key enzymatic processes involved in viral replication. By disrupting the activity of this enzyme, CNP0296775 shows promise in studying dengue virus pathogenesis and could serve as a valuable tool in antiviral research. Its application in preclinical studies may aid in the development of novel therapeutic strategies for dengue virus infections. -
NS2B-NS3 Inhibitor
NS2B/NS3-IN-9 is a non-competitive inhibitor targeting the NS2B-NS3 protease of Orthoflavivirus, demonstrating broad-spectrum antiviral activity. It exhibits IC50 values of 2.4 μM, 7.2 μM, and 1.9 μM against the Dengue virus DENV2, West Nile virus WNV, and Zika virus ZIKV, respectively. Additionally, NS2B/NS3-IN-9 shows cellular EC50 values of 4.1 μM for DENV2, 4.9 μM for WNV, and 5.0 μM for ZIKV, while exhibiting minimal toxicity to host cells. This compound is suitable for research applications focused on inhibiting Orthoflavivirus infections. -
NS2B·NS3 Protease Inhibitor
CN-716 dihydrochloride is a reversible covalent inhibitor targeting the NS2B·NS3 protease of flaviviruses, demonstrating significant antiviral activity. This compound effectively impedes the replication of dengue virus (DENV2), West Nile virus (WNV), and Zika virus (ZIKV), with IC50 values of 0.066 μM, 0.11 μM, and 0.25 μM, respectively. Additionally, CN-716 dihydrochloride exhibits Ki values of 0.051 μM, 0.082 μM, and 0.04 μM against the same proteases. It serves as a valuable tool for investigating the infection mechanisms associated with dengue fever, West Nile fever, and Zika virus infection. -
NS2B-NS3 Inhibitor
Ac-EVKKQR-pNA is a competitive chromogenic para-nitroanilide substrate designed to probe the NS2B-NS3 cleavage site. This reagent includes a readily hydrolyzable para-nitroanilide at the P1’ position, enhancing its reactivity. It is primarily used in studies of dengue virus type 2 and other flavivirus infections, facilitating the exploration of viral protease activity and potential therapeutic interventions. -
AAK1 Inhibitor
AAK1-IN-6 is a potent inhibitor of AP-2-associated protein kinase 1 (AAK1) with an IC50 value of 12 nM. This compound exhibits significant antiviral activity against dengue virus (DNEV2, EC50 = 0.24 μM) and Venezuelan equine encephalitis virus (VEEV, EC50 = 0.30 μM). AAK1-IN-6 is a valuable tool for researchers investigating antiviral mechanisms and potential therapeutic strategies. -
NS2B-NS3/thrombin Inhibitor
5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione is a potent inhibitor of the dengue virus NS2B-NS3 protease and thrombin. This compound is valuable for studying the mechanisms of viral replication and coagulation processes, making it an essential tool in research focused on infectious diseases and related therapeutic interventions. Its dual activity highlights its potential for investigating the dynamics of viral pathology and thrombotic complications. -
HIV Protease Inhibitor
2α,19α-Dihydroxy-3-oxo-urs-12-en-28-oic acid is identified as a potent inhibitor of HIV protease, exhibiting significant antiviral activity. Additionally, this compound inhibits the activation of Epstein-Barr virus early antigen (EBV-EA), demonstrating its utility in virology research. Furthermore, it displays inhibitory effects on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells, highlighting its potential applications in immunology and inflammation studies. -
EV71 Inhibitor
Gylongiposide I is a selective inhibitor targeting enterovirus EV71, demonstrating an EC50 of 1.53 μM. It exerts antiviral activity by decreasing the expression of viral protein VP1 and reducing levels of viral genomic RNA. This compound is valuable for research and development of therapeutic agents aimed at combating hand, foot, and mouth disease associated with EV71. -
Enterovirus 71 Inhibitor
Norwogonin is an antiviral compound isolated from Scutellaria baicalensis Georgi that specifically targets Enterovirus 71 (EV71). It demonstrates a potent inhibitory effect, with an IC50 value of 31.83 μg/ml, making it a valuable tool for research in viral infection mechanisms and potential therapeutic strategies against EV71. This compound can contribute to studies focused on antiviral drug development and the exploration of natural product-derived therapeutics. -
EV71 Inhibitor
DMA-135 hydrochloride is a specific inhibitor of enterovirus 71 (EV71) that targets the IRES-dependent translation and replication pathways. It binds to the EV71 SLII domain with a moderately high affinity (KD = 520 nM), effectively suppressing viral activity. This compound exhibits minimal toxicity in cell-based studies, making it an important tool for research in virology and potential therapeutic applications against EV71 infections. -
Monoamine Oxidase Inhibitor
Pirlindole is a selective and reversible inhibitor of monoamine oxidase A (MAO-A). This compound exhibits significant antiviral activity against enterovirus-D68 and coxsackievirus B3 (CV-B3). Pirlindole is primarily utilized in research focusing on the modulation of monoamine levels and the investigation of viral pathologies. -
Glucosidase Inhibitor
Ganoderic acid Y is an α-glucosidase inhibitor, exhibiting an IC50 of 170 μM against yeast α-glucosidase. This compound demonstrates antiviral properties by inhibiting the replication of enterovirus 71 (EV71) through the disruption of the virus uncoating process. Ganoderic acid Y is relevant for research applications investigating glycosidase activity and antiviral strategies. -
EV71 3C Protease Inhibitor
DC07090 dihydrochloride is a potent, reversible, and competitive inhibitor of the human enterovirus 71 (EV71) 3C protease. It exhibits low toxicity with an IC50 of 21.72 μM and a Ki value of 23.29 μM. Additionally, DC07090 dihydrochloride effectively inhibits coxsackievirus A16 (CVA16) replication, with an EC50 of 27.76 μM. This compound is valuable for research into enteroviral infections and potential therapeutic interventions against these viruses. -
EV71 Inhibitor
Methyl 3,4-dihydroxyphenylacetate is a potent inhibitor of enterovirus 71 (EV71) replication. This compound effectively reduces viral replication in rhabdomyosarcoma (RD) cells, highlighting its potential as an antiviral agent. Its biological activity makes it valuable for research into therapeutic strategies against EV71 and other enteroviral infections. -
Polioviruses Inhibitor
Disoxaril is a potent inhibitor of polioviruses, effectively impeding the replication of types 1 and 2 within host cells. It operates by binding to virion capsid proteins, facilitating viral uncoating stabilization, while still permitting virus entry through receptor-mediated endocytosis. Additionally, Disoxaril demonstrates inhibitory activity against enterovirus replication, making it a valuable reagent for virology research and studies on enterovirus-related diseases. -
Enterovirus Inhibitor
Antiviral agent 23 is a potent inhibitor of enterovirus 71 (EV71) with an EC50 value of 94 nM. It effectively suppresses the activity of the methyltransferase complex METTL3/METTL14, demonstrating significant antiviral activity. This compound is suitable for research focused on enteroviral infections and the mechanisms of RNA modification in viral pathogenesis. -
HIV/EV-A71 Inhibitor
AL-470 is a potent antiviral compound targeting HIV-1, HIV-2, and EV-A71, exhibiting EC50 values of 0.27 µM, 0.63 µM, and 0.35 µM, respectively. This compound demonstrates significant inhibition of viral replication and is suitable for studies focused on HIV and enterovirus A71 infections. AL-470 serves as a valuable tool for researchers investigating antiviral mechanisms and therapeutic strategies against these viral pathogens. -
Enteroviru Inhibitor
R78206 is an antiviral pyridazinamine compound that targets enteroviruses by providing protection against thermal inactivation. This compound exhibits varied effects on different strains of poliovirus depending on concentration and demonstrates a potent stabilizing effect on Mahoney procapsids. R78206 is valuable for research applications focused on enteroviral pathogenesis and potential therapeutic interventions. -
EV71 3C Protease Inhibitor
DC07090 is a potent, reversible, and competitive inhibitor of the human enterovirus 71 (EV71) 3C protease, with an IC50 of 21.72 μM and a Ki value of 23.29 μM. This compound also demonstrates inhibitory activity against coxsackievirus A16 (CVA16) replication, exhibiting an EC50 value of 27.76 μM. DC07090 is valuable for research applications focused on the development of antiviral strategies targeting enteroviruses. -
EV-A71 Inhibitor
EV-A71-IN-1 is an inhibitor targeting the human enterovirus A71 (EV-A71) capsid protein, exhibiting an EC50 of 0.27 μM. This compound functions as a capsid binder, effectively interfering with the interaction between the viral VP1 protein and the host receptor hSCARB2. Additionally, EV-A71-IN-1 demonstrates broad inhibitory activity against various human enteroviruses while maintaining low cytotoxicity (CC50 > 56.2 μM), making it a valuable tool for research on enteroviral infections and potential therapeutic interventions. -
MAO-A Inhibitor
Pirlindole mesylate is a selective and reversible inhibitor of monoamine oxidase A (MAO-A), playing a crucial role in the modulation of neurotransmitter metabolism. Additionally, Pirlindole exhibits antiviral activity against enterovirus D68 and coxsackievirus B3 (CV-B3), positioning it as a potential agent in virology research. This compound is valuable for studies focusing on depression, anxiety disorders, and the therapeutic mechanisms of neuronal regulation and viral infections. -
ROC/EV-A71 Inhibitor
Fukinolic acid serves as a receptor-operated Ca2+ channel (ROC) inhibitor, effectively suppressing extracellular Ca2+ influx activated by norepinephrine while preserving the function of voltage-dependent Ca2+ channels. This compound demonstrates notable antiviral activity against enterovirus A71 (EV-A71) replication, making it a valuable tool in research related to enteroviral infections. Additionally, its vasodilatory properties further enhance its potential applications in cardiovascular studies. -
Enteroviruses Replication Inhibitor
MRL-1237 is an enterovirus replication inhibitor that targets the non-structural protein 2C. It demonstrates effective inhibition of poliovirus and other enteroviruses, making it a valuable tool for studying viral infections. Notably, MRL-1237 does not interfere with the NTPase (ATPase) activity of the 2C protein, allowing for specific mechanistic investigations in enteroviral research applications. -
EVs 2C Inhibitor
Jun15716 is an inhibitor of the Enterovirus (EVs) 2C protein, exhibiting dissociation constants (Kis) of 15.9, 44.2, and 17.8 μM for EV-D68, EV-A71, and CVB3, respectively. This compound demonstrates significant antiviral activity, with effective concentrations (EC50) of 1.0 μM against EV-D68 and 0.7 μM against CVB3 in relevant cellular models. Jun15716 is applicable in virology research, particularly in studies related to viral infections such as meningitis, hand, foot and mouth disease (HFMD), and viral myocarditis. -
2C Inhibitor
R523062 is a viral 2C inhibitor that targets the 2C protein of enteroviruses. This compound effectively reduces the levels of the viral VP1 protein, thereby impairing viral replication. R523062 exhibits broad-spectrum antiviral activity against enterovirus D68 (EV-D68) strains, making it a valuable tool for research in antiviral therapeutics and virology. -
CV-B3 2C ATPase Inhibitor
ATPase-IN-8 is a selective inhibitor of CV-B3 2C ATPase, exhibiting an IC50 of 1.4 μM. This compound demonstrates significant anti-enteroviral activity, particularly against coxsackievirus B3 (CV-B3) and enterovirus D68 (EV-D68). ATPase-IN-8 is suitable for research applications focusing on enteroviral infections and their molecular mechanisms. -
EV71 Inhibitor
ZHSI-1 is a potent inhibitor of Enterovirus 71 (EV71), targeting viral replication and mitigating virus-induced pyroptosis linked to pathogenesis. This compound effectively prevents EV71 infection in neonatal and young murine models, making it a valuable tool for research in viral infections, specifically related to hand, foot, and mouth disease (HFMD). Its application may contribute to the understanding of EV71 behavior and aid in developing therapeutic strategies against this virus. -
NS2B-NS3 Protease Inhibitor
NS2B/NS3-IN-3 is a potent inhibitor of the Flavivirus NS2B-NS3 protease, which plays a critical role in viral polyprotein processing. This compound demonstrates significant antiviral activity, making it a valuable tool for research investigating Flavivirus infections and potential therapeutic strategies. Applications include studies on protease inhibition mechanisms and the development of antiviral drugs targeting flavivirus-related diseases. -
Flavivirus NS2B-NS3 Inhibitor
NS2B/NS3-IN-3 hydrochloride is a potent inhibitor of the Flavivirus NS2B-NS3 protease, crucial for the viral replication cycle. This compound selectively disrupts the protease activity, demonstrating significant antiviral efficacy. It serves as a valuable tool for research applications focused on understanding Flavivirus pathogenesis and developing new antiviral therapies. -
DENV Inhibitor
(-)-JNJ-A07 is a potent and selective inhibitor of Dengue Virus (DENV) with an EC50 value of 31 nM. It demonstrates significant antiviral activity, making it a valuable tool for research in virology and the study of DENV pathogenesis. This compound is suitable for investigations into potential therapeutic strategies for dengue fever and other flavivirus-related diseases. -
Yellow Fever Virus Inhibitor
RCB16007 is a selective inhibitor of the Yellow Fever Virus (YFV). It demonstrates effective antiviral activity against the West Nile virus, with an EC50 value of 7.9 μM and a CC50 of 17 μM. This compound serves as a valuable tool for studies related to flavivirus infections and can aid in the development of therapeutics targeting RNA viruses. -
IMPDH Inhibitor
Mycophenolic acid-13C17 is a stable isotope-labeled form of Mycophenolic acid, acting as a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) with an EC50 of 0.24 μM. This compound exhibits significant antiviral activity against a variety of RNA viruses, including influenza, and serves as an immunosuppressive agent. Additionally, Mycophenolic acid-13C17 demonstrates antiangiogenic and antitumor properties, making it valuable for research in immunology, virology, and cancer biology. -
δ-Opioid Receptor Antagonist/DENV Inhibitor
SDM25N hydrochloride is a potent δ-opioid receptor antagonist that also serves as an effective inhibitor of the dengue virus (DENV). It specifically targets the viral NS4B protein, significantly limiting genomic RNA replication. This compound presents valuable opportunities for research on antiviral strategies and the role of δ-opioid receptors in viral pathogenesis. -
NS5 RdRp/NS2B-NS3pro Inhibitor
LabMol-301 is a potent inhibitor of both NS5 RNA-dependent RNA polymerase (RdRp) and NS2B-NS3 protease, with IC50 values of 0.8 μM and 7.4 μM, respectively. This reagent demonstrates cytoprotective properties by effectively preventing cell death induced by the Zika virus (ZIKV). LabMol-301 is valuable for research applications focusing on antiviral drug development and the mechanistic study of flavivirus pathogenesis. -
STT3A-mediated Mega Protein Complex Assembly Inhibitor
NSC-323241 is an STT3A-mediated mega protein complex assembly inhibitor that effectively disrupts the endoplasmic reticulum (ER) mega complex essential for dengue virus (DENV) and Zika virus (ZIKV) infection. By targeting the interaction between the STT3A subcomplex, viral nonstructural proteins (e.g., NS2B, NS3), and host translocon proteins, NSC-323241 impedes the establishment of the viral replication microenvironment. This compound is valuable for investigating the mechanisms of flavivirus infections, including dengue fever and Zika virus. -
Flavivirus inhibitor
Flaviviruses-IN-1 is a potent inhibitor of various viruses within the Flaviviridae family, acting primarily by modulating the host cell immune response to viral infection. This compound has demonstrated significant efficacy in preventing viral replication and infection, making it a valuable tool in virology research. Flaviviruses-IN-1 was identified through high-throughput screening as a promising candidate for therapeutic development against flavivirus infections, offering new avenues for intervention in related diseases. -
Flaviviru Inhibitor
TYT-1 is a sulfonamide-thiourea compound that targets flavivirus replication. It demonstrates potent inhibitory activity against West Nile virus, with a 50% effective concentration of 0.7 µM, effectively blocking a post-entry, pre-assembly step in the viral life cycle. This compound is valuable for research applications focused on understanding flavivirus pathogenesis and developing antiviral strategies. -
Rna Virus Inhibitor
Galidesivir dihydrochloride is a broad-spectrum RNA virus inhibitor targeting various RNA viruses, including Ebola and yellow fever viruses. This compound exhibits potent antiviral activity against tick-borne encephalitis virus (TBEV) and inhibits the proliferation of several other medically significant flaviviruses. Its efficacy makes Galidesivir a valuable tool for research applications focused on viral pathogenesis and antiviral drug development. -
ZIKV NS2B-NS3 Protease Inhibitor
IRBM-Z-1 is a non-competitive inhibitor targeting the Zika virus (ZIKV) NS2B-NS3 protease, demonstrating an IC50 of 1.8 μM. This compound also effectively inhibits the NS2B-NS3 proteases of T156I-mutated dengue virus 2 (DENV2) and West Nile virus (WNV), with IC50 values of 3.9 μM and 4.7 μM, respectively. IRBM-Z-1 is capable of inhibiting ZIKV replication and reducing virus-induced cytopathic effects, making it a valuable tool for research focused on ZIKV infection and associated viral pathogenesis. -
ZIKV NS2B-NS3 Protease Inhibitor
IRBM-Z-2 is an orally active, non-competitive inhibitor targeting the Zika virus (ZIKV) NS2B-NS3 protease, demonstrating IC50 values of 0.04 μM for the wild-type and 3.1 μM for the I156T mutant strains. This compound exhibits broad-spectrum activity against flaviviruses, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus serotype 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-2 effectively inhibits ZIKV replication and mitigates virus-induced cytopathic effects, making it a valuable tool for research on ZIKV infection and the study of flavivirus-related diseases. -
HBV Inhibitor
Adefovir is an adenosine monophosphate analog that targets HBV DNA polymerase, exerting its inhibitory effects through conversion to Adefovir diphosphate within cells. Demonstrating an IC50 of 0.7 μM against Hepatitis B Virus (HBV) in the HepG2.2.15 cell line, Adefovir exhibits strong antiviral properties against HBV and other herpesviruses. It is a valuable reagent for research into antiviral therapies and HBV-related studies. -
Nucleoside Reverse Transcriptase Inhibitor
Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with notable antiviral activity against HIV, HBV, and HCV. It exhibits strong inhibition of HIV-1 and HIV-2, with EC50 values ranging from 0.018 to 6.92 nM, and effectively targets NRTI-resistant strains. Additionally, Azvudine serves as a click chemistry reagent, featuring an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those with DBCO or BCN groups, making it suitable for advanced chemical biology applications. -
HIV/HBV Inhibitor
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate, a phosphorylated metabolite of Emtricitabine. This compound functions as a nucleoside reverse transcriptase inhibitor, effectively targeting both HIV and HBV. Emtricitabine triphosphate tetrasodium salt is utilized in research applications focused on antiviral drug development and the mechanisms of viral replication. -
HBV Inhibitor
Vebicorvir is a first-generation inhibitor targeting the hepatitis B virus (HBV) core protein. It effectively suppresses the formation of covalently closed circular DNA (cccDNA) in various de novo infection models, demonstrating effective inhibition with EC50 values ranging from 1.84 μM to 7.3 μM. This compound is valuable for research applications focused on developing therapeutic strategies against HBV infections. -
HIV Inhibitor
(S)-Tenofovir is an S-enantiomer of Tenofovir, functioning primarily as a nucleotide reverse transcriptase inhibitor. This compound demonstrates significant biological activity against HIV and is also relevant in the treatment of chronic Hepatitis B (HBV). It is commonly utilized in research applications focused on antiviral therapies and the mechanistic study of retroviral infections. -
HBV Inhibitor
Inarigivir ammonium is a potent HBV inhibitor that functions as a RIG-I (Retinoic acid-inducible gene-I) agonist, stimulating the innate immune response to combat hepatitis B virus infection. This compound has demonstrated effectiveness in significantly reducing liver HBV DNA levels in transgenic mouse models. Due to its mechanism of action, Inarigivir ammonium is positioned as a valuable tool for research in antiviral therapies and the study of hepatitis B virus dynamics. -
HBV Inhibitor
5-O-(E)-p-Coumaroylquinic acid is a quinic acid derivative that serves as a potent inhibitor of hepatitis B virus (HBV). This compound exhibits significant antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its unique structural properties may provide insights into the development of novel antiviral agents targeting viral replication. -
HBV Inhibitor
Schisantherin C is a potent inhibitor of hepatitis B virus (HBV) with demonstrated efficacy in reducing hepatocyte secretions of HBsAg and HBeAg by 59.7% and 34.7%, respectively, at a concentration of 50 μg/mL. This compound holds potential for research applications aimed at understanding HBV pathogenesis and developing effective antiviral therapies. -
HBV Inhibitor
ALG-001075 functions as a capsid assembly modulator (CAM) and serves as an orally active inhibitor of hepatitis B virus (HBV). This compound effectively inhibits HBV DNA production, along with extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. In the AAV-HBV mouse model, ALG-001075 demonstrates significant reductions in circulating HBV DNA. It is valuable for research applications focused on chronic hepatitis B (CHB). -
HBV Inhibitor
SAG-524 is a highly effective small molecule inhibitor targeting hepatitis B virus (HBV) replication. It demonstrates significant antiviral activity, reducing HBV-DNA and HBsAg levels in supernatants of HepG2.2.15 cells, with IC50 values of 0.92 nM and 1.4 nM, respectively. SAG-524 is valuable for research focused on HBV biology and therapeutic development for liver diseases associated with viral infections.
